Related Experiment Video
Updated: Aug 12, 2026

Electrolytic Inferior Vena Cava Model (EIM) of Venous Thrombosis
Published on: July 12, 2011
Hyperhomocysteinemia and venous thrombosis
1University Hospital Rotterdam/Daniel den Hoed Cancer Center, The Netherlands.
Insights
Hyperhomocysteinemia is a risk factor for vascular issues like venous thrombosis. While easily treated with vitamins, ongoing studies investigate if lowering homocysteine levels prevents recurrent thrombosis.
Area of Science:
- Cardiovascular Medicine
- Thrombosis Research
Background:
- Hyperhomocysteinemia is increasingly recognized as a risk factor for various conditions, including neural tube defects, arterial cardiovascular disease, and venous thrombosis.
- The association between hyperhomocysteinemia and vascular diseases, particularly venous thrombosis, has garnered significant attention.
Purpose of the Study:
- To discuss hyperhomocysteinemia, its causes, and its association with venous thrombosis.
- To evaluate the diagnostic utility of the methionine loading test for hyperhomocysteinemia.
- To explore therapeutic options and ongoing research into the clinical relevance of lowering homocysteine levels for preventing recurrent venous thrombosis.
Main Methods:
- Review of existing case-control and prospective studies on hyperhomocysteinemia and venous thrombosis.
- Discussion of potential mechanisms linking hyperhomocysteinemia to venous thrombosis.
- Description of a current international multicenter, placebo-controlled study investigating the efficacy of homocysteine level reduction.
Main Results:
- Several case-control studies suggest an association between venous thrombosis and hyperhomocysteinemia.
- Evidence for a causal relationship, especially for mild hyperhomocysteinemia, remains limited.
- Hyperhomocysteinemia is generally treatable with vitamin supplementation.
Conclusions:
- While an association exists, the causal role of mild hyperhomocysteinemia in venous thrombosis requires further investigation.
- Ongoing research aims to determine the clinical significance of reducing homocysteine levels in preventing recurrent venous thrombosis.
Abstract:
In recent years hyperhomocysteinemia has been established as a new risk factor for neural tube defects, arterial cardiovascular disease, and venous thrombosis. Concerning vascular problems, it first became clear that hyperhomocysteinemia might be (though not proven) a risk factor for arterial disease as observed in case-control studies, as well as in prospective analysis. More recently, the subject of hyperhomocysteinemia and venous thrombosis has received much attention. In this article, we discuss the issue of hyperhomocysteinemia, in general, the known causes of hyperhomocysteinemia and the association with venous thrombosis. Special attention is given to the value of the methionine loading test to diagnose hyperhomocysteinemia. An association of venous thrombosis and hyperhomocysteinemia has now been documented in several case control studies, but only in one prospective analysis. Thus far, there is limited evidence for a causal relationship for mild hyperhomocysteinemia in venous thrombosis. Briefly, the possible mechanisms of how hyperhomocysteinemia can lead to venous thrombosis are discussed. The article ends with therapeutic options to treat hyperhomocysteinemia (hyperhomocysteinemia can easily be treated with vitamins) and the description of a study that is presently being undertaken in an international multicenter design. This placebo-controlled study might resolve the question of whether lowering of homocysteine levels is of any clinical relevance in preventing recurrent venous thrombosis.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management

